We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Biobanking Global Summit

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Join the industry professionals in attendance at the Old Royal Naval College - Greenwich, London, UK on the 12th - 13th Sept 2011 for a chance to discuss the latest trends and developments in Biobanking.

An estimated $1bn has been invested in the biobanking industry within the last ten years.  Biobanks are proving to be a fundamental instrument in the future of drug discovery. At least 179 biobanks with 345,000 donors exist in the US, most of which were established in the last 10 years. (Source: Business Insights, March 2009). Biobanks are under constant pressure to meet quality standards, international regulations and to attract further investors for progressive expansion.

Appel Consulting’s Biobanking conference tackles these issues with a fresh perspective; join our unique summit today.

Network with senior level executives from the top 20 pharmaceutical and biotechnology industries. Our summit will focus on Harmonising Biobanking Research and Maximising Business Development. Hear key addresses from industry leaders  concerning The Future of Virtual Biobanking Models. Scientific presentations will provide in-depth coverage on topics including Biobanking and Gene Expression Profiling,
Coordination of Cancer Biobanking in the UK, Challenges in breast tissue biobanking and Intergrating clinical study data with Biobank software with sessions dedicated to maximising utility of human biological samples .

The conference will focus on main areas of:

1) Optimising sample collection & validation techniques to ensure sample integrity
2) Challenges associated with developing & maintaining a biobank
3) Incorporating informatics into biobanking
4) Utilising biospecimens for drug development
5) The future economics of biobanking:implementing new technology
6) Business development and management strategies for efficient biobanking

Hear keynote addresses from:

•Dr Steve Kelly, Head Neuroscience, AstraZeneca
•Prof Massimo Pignatelli, Director, NHS Greater Glasgow & Clyde Bio-repository
•Dr Marc Hooijer, Founder & CEO, SampleNavigator
•Dr Alice Matimba, Research Fellow, Mayo Clinic, USA
•Dr Margaret Clotworthy, Director, Human Focused Testing
•Dr Graham Wilson, Business Development Manager, Labvantage
•Dr Ruth McLaughlin, Business Development Manager, Biopta